Eton Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration declined to approve its anti-seizure drug lamotrigine, sending the drugmaker's shares down 13% in extended trading.
Register now for FREE unlimited access to Reuters.comThe drug is a liquid form of a widely available anticonvulsant or antiepileptic oral tablet, which also goes by the name lamotrigine. It helps stabilize electrical activity inside the brain and makes it harder for certain neurons to get stimulated, thus preventing seizures.
The drugmaker did not disclose the details of the complete response letter and added that it was assessing the FDA's comments along with its partner. Eton and Azurity did not immediately respond to Reuters' requests for more details on the complete response letter. In 2020, the FDA declined to approve the use of the drug, citing the need for an additional study to show that patients can prepare and administer the oral suspension safely and effectively.
The drugmaker's partner submitted results from the additional study to the FDA in the fourth quarter of 2021.Reporting by Bhanvi Satija and Mrinalika Roy in Bengaluru; Editing by Amy Caren DanielSign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Nurse From Liberia Holds 'Clap for Pharma Profits' Protest at Davos\u0022Me and my frontline colleagues saw pain, misery, death,\u0022 said George Poe Williams. \u0022Bourla and the other pharma executives here in Davos saw a chance to pump up profits.\u0022
Lire la suite »
New alopecia drug regrows hair in 40% of patients — FDA approval soughtThe latest trial studied 706 adults who have alopecia, aged 18 to 65, for 24 weeks in the US, Canada and Europe.
Lire la suite »
Almost 2 million more cans of baby formula headed to U.S. from overseas, FDA saysBubs Australia and Danone's Nutricia will provide baby formula to help alleviate the shortage in the U.S.
Lire la suite »
FDA Commissioner Urges U.S. Baby-Formula StockpileThe commissioner of the FDA told Senators probing the baby formula shortage that the U.S. should create a stockpile, and said recent moves to increase supplies should produce a surplus in about two months
Lire la suite »
Analysis: Stock and bond divergence offers hope for battered 60/40 portfolioU.S. stocks and bonds are moving in opposite directions, a phenomenon that could bring relief for investors hoping for a blend of the two asset classes to blunt declines in their portfolios.
Lire la suite »
Exclusive: U.S. buys more Stingers after missiles' success in UkraineThe U.S. Army has signed a deal to buy $687 million worth of anti-aircraft Stinger missiles to replenish stocks sent to Ukraine, sources said on Friday.
Lire la suite »